April 2014
Volume 55, Issue 13
Free
ARVO Annual Meeting Abstract  |   April 2014
Melatonin, IIK7 and 5-MCA-NAT potentiate adrenergic receptor-mediated ocular hypotensive effects in rabbits: significance for combination therapy in glaucoma
Author Affiliations & Notes
  • Alejandro Martínez-Águila
    Biochemistry and Molecular Biology IV, Complutense University, Madrid, Spain
  • Almudena Crooke
    Biochemistry and Molecular Biology IV, Complutense University, Madrid, Spain
  • Fernando Huete-Toral
    Biochemistry and Molecular Biology IV, Complutense University, Madrid, Spain
  • Alba Martin-Gil
    Biochemistry and Molecular Biology IV, Complutense University, Madrid, Spain
  • Begoña Fonseca
    Biochemistry and Molecular Biology IV, Complutense University, Madrid, Spain
  • Jesus Pintor
    Biochemistry and Molecular Biology IV, Complutense University, Madrid, Spain
  • Footnotes
    Commercial Relationships Alejandro Martínez-Águila, None; Almudena Crooke, None; Fernando Huete-Toral, None; Alba Martin-Gil, None; Begoña Fonseca, None; Jesus Pintor, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science April 2014, Vol.55, 2897. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Alejandro Martínez-Águila, Almudena Crooke, Fernando Huete-Toral, Alba Martin-Gil, Begoña Fonseca, Jesus Pintor; Melatonin, IIK7 and 5-MCA-NAT potentiate adrenergic receptor-mediated ocular hypotensive effects in rabbits: significance for combination therapy in glaucoma. Invest. Ophthalmol. Vis. Sci. 2014;55(13):2897.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: To investigate the possible potentiating effect of melatoninergic drugs upon the ocular hypotensive action of brimonidine, a selective α2-adrenergic receptor agonist (Alphagan), and timolol, a nonselective β-adrenergic receptor antagonist (Timoftol).

Methods: Male New Zealand white rabbits, weighing 3-4 kg, were used for IOP studies. IIK7, melatonin and 5-MCA-NAT were formulated in isotonic saline containing 1% dimethylsulfoxide (DMSO) and were tested at a final concentration of 100 μM. Alphagan 0.2% (brimonidine) and Timoftol 0.5% (timolol) were instilled at a fixed volume of 40 μl. Studies of mRNA and protein expression were conducted using immortalized rabbit nonpigmented ciliary epithelial (NPE) cells. Total RNA was isolated using the RNeasy Minikit (Qiagen), according to the manufacturer’s protocol. Immunofluorescent staining was performed to evaluate α2A- and β2-adrenergic receptor expression in rabbit NPE cells treated with melatonin and 5-MCA-NAT.

Results: Intraocular pressure (IOP) experiments showed that the pretreatment with IIK7, melatonin or 5-MCA-NAT increased the hypotensive effect of timolol in 10.84% ± 4.11% (P< 0.05), 14.02% ± 5.8% and 16.75% ± 5.48% (P< 0.01), respectively, in rabbits for 24 hours. Concerning brimonidine hypotensive action, an additional IOP reduction of 32.11% ± 4.68%, 29.26% ± 5.21% and 39.07% ± 5.81% (P< 0.001) were observed in rabbits pretreated with IIK7, melatonin or 5-MCA-NAT, respectively, when compared with animals treated with brimonidine alone for 24 hours. Additionally, a sustained potentiating effect of a single dose of IIK7 and 5-MCA-NAT were seen in rabbits treated with brimonidine once daily for up 4 days (extra IOP decrease of 16.61% ± 5.12% and 15.57% ± 5.15% (P< 0.05), compared with brimonidine alone).

Conclusions: These data confirm the indirect action of melatoninergic compounds on adrenergic receptors and their remarkable effect upon the ocular hypotensive action mainly of α2-adrenergic receptor agonists but also of β-adrenergic antagonists.

Keywords: 568 intraocular pressure • 675 receptors: pharmacology/physiology  
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×